) for a scientific commentary on this article.
Introduction
Discovered only a few years ago, anti-NMDA receptor (NMDAR) encephalitis has become one of the most commonly identified causes of encephalitis and an important differential diagnosis for new-onset psychosis, characteristically associated with hallucinations, catatonia, altered levels of consciousness, seizures, hypoventilation, dyskinesias, and autonomic dysfunction (Dalmau et al., 2007) . Despite its often severe course requiring prolonged episodes of intensive care unit treatment and mechanical ventilation, a majority of patients show marked recovery with sufficient immunotherapy (Titulaer et al., 2013) . Clinical diagnosis can be established when serum or CSF antibodies bind to the NR1 subunit of the NMDAR, routinely tested with cell-based assays using NR1-transfected human embryonic kidney cells (Peery et al., 2012) .
The relevance of a predominantly humoral immune response in NMDAR encephalitis has been concluded from the beneficial effect of plasma exchange, which is widely considered as first-line immunotherapy (Titulaer et al., 2013) , and from experiments with human specimen-derived immunoglobulins containing NMDAR antibodies that downregulated NMDAR in vitro and in vivo (Hughes et al., 2010; Prü ss et al., 2010; Mikasova et al., 2012; Moscato et al., 2014; Planaguma et al., 2015) . Previous work showed that patients' immunoglobulin contained antibodies that target an epitope in the amino terminal domain of the receptor (Gleichman et al., 2012) . However, little is known about which cells produce the antibodies in the CNS, the molecular features of NMDAR autoantibodies, and the frequency of cells producing non-NMDAR binding antibodies in the CSF of patients with NMDAR encephalitis. More importantly, these previous studies could not discriminate between the effect of NMDAR antibodies and the contribution of further anti-neuronal autoantibodies present in CSF. Indeed, diagnostic laboratories commonly identify antibodybinding to brain structures beyond the NR1 immunofluorescence staining pattern, and some clinical features of the disease are not well explained by downregulation of NMDARs, such as susceptibility to epileptic seizures, which has so far been associated with increased or unchanged receptor expression (Kalev-Zylinska et al., 2009; Wasterlain et al., 2013; Wright et al., 2015) . Thus, ultimate proof is lacking that NMDAR antibodies alone are sufficient to cause neuronal receptor downregulation and electrophysiological changes associated with the disease.
We therefore aimed to characterize the monoclonal antibody repertoire from CSF antibody-secreting cells and memory B cells of patients with NMDAR encephalitis. In an unbiased approach we generated recombinant monoclonal antibodies by single cell cloning and sequencing of fulllength immunoglobulin heavy, kappa and lambda light chain genes. We demonstrate that patients mount a polyclonal antibody response against NMDAR and many further neuronal proteins, and that NMDAR binding of monoclonal recombinant NR1 antibodies generated from patients is sufficient to cause NMDAR downregulation and functional impairment of NMDAR-mediated currents.
Materials and methods

Study approval
All mice were used according to the Berlin LaGeSo Standing Committee on Animals. All clinical investigations were conducted according to Declaration of Helsinki principles. Written informed consent was received from participants at the Charité Department of Neurology or their representatives prior to inclusion in the study and analyses were approved by the Charité University Hospital Institutional Review Board.
CSF single cell isolation
Single cell sorting was performed as previously described (Tiller et al., 2008) . In brief, fresh CSF samples were transferred on ice and immediately centrifuged at 400g for 10 min. The supernatant was removed and cells resuspended in 500 ml freezing medium [45% RPMI, 45% foetal calf serum, 10% dimethylsulphoxide (DMSO)] and stored at À80 C. For fluorescence-activated cell sorting (FACS) into 96-well PCR plates using a FACSAria TM II (BD Biosciences), frozen cells were thawed, diluted in phosphatebuffered saline (PBS) and stained on ice with antibodies from BioLegend (anti-CD16, 1:50; Zombie Yellow, 1:100), Miltenyi Biotec (anti-CD20, 1:40; anti-CD27, 1:11; anti-CD38, 1:50; antiIgD, 1:22), and own supply (Flow Cytometry Core Facility, MPIIB) (anti-CD3, 1:100; anti-CD14, 1:50). Each well contained 4 ml of ice-cold lysis solution of 0.5Â PBS with 10 mM DTT (Invitrogen) and 8 U RNasin Õ (Promega).
Polymerase chain reaction strategy
Single cell reverse transcriptase-polymerase chain reaction (RT-PCR) was performed as previously described (Tiller et al., 2008) 
Immunoglobulin sequence analysis
The second PCR products were sequenced (GATC Biotech) with reverse primers for IGH, IGK and IGL (Supplementary  Table 2 ). Sequences were compared by IgBLAST with GenBank (http://www.ncbi.nlm.nih.gov/igblast/) to identify germline V(D)J gene segments with highest sequence homology (Corbett et al., 1997) . For each immunoglobulin chain sequence the number of somatic hypermutations in the immunoglobulin gene were counted in comparison to the annotated germline sequences as well as the length of the complementarity determining region (CDR3) as described previously (Kabat et al., 1983; Kabat and Wu, 1991) .
Cloning into expression vectors
Immunoglobulin gene cloning was performed as previously described (Tiller et al., 2008) . Restriction sites were introduced into heavy and light chains for each immunoglobulin (AgeI and SalI for IGH, AgeI and BsiWI for IGK, AgeI and XhoI for IGL) using individual immunoglobulin gene-specific primers (Supplementary Table 2 ). PCR conditions were as above for the second PCR for heavy chains. Restriction digest was performed at 37 C for 1 h in 40 ml with 31.5 ml of purified specific PCR product and 1 U of each enzyme AgeI, SalI and XhoI (New England Biolabs). Only for IGK samples, 1 U of BsiWI enzyme was added and secondarily digested at 55 C for 1 h. Purified products were ligated into expression vectors containing human IGHG1, IGK and IGL constant regions, respectively with a cytomegalovirus (CMV) promotor and ampicillin resistance (Wardemann et al., 2003; Tiller et al., 2008) . Ligation product (2.5 ml) was transformed into 6 ml of high efficiency 10-beta competent Escherichia coli bacteria (NEB). Positive colonies were screened for inserts (650 bp for IGHG1, 700 bp for IGK and 590 bp for IGL) by PCR (primers as in Supplementary 
Recombinant monoclonal antibodies
Antibody production was performed as previously described (Tiller et al., 2008) . In brief, human embryonic kidney (HEK293T) cells were cultured in 6-well plates in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% heat-inactivated foetal bovine serum (FBS), 100 U/ml penicillin, and 100 mg/ml streptomycin (Gibco Life Technologies). At 60-80% confluence, cells were transiently transfected in DMEM supplemented with 1% Nutridoma-SP (Roche), 100 U/ml penicillin, and 100 mg/ml streptomycin with a transfection solution of 75 ml sterile sodium chloride, 0.75 mg HC vector, 0.75 mg LC vector and 7.5 ml polyethylenimine (PEI, 0.6 g/l) solution (Sigma-Aldrich). Supernatant was harvested after 3 and 5 days. Antibody concentration was on average 30 mg/ml ranging from 10 to 80 mg/ml.
Antibody purification
Supernatant was incubated with 2 ml Protein G Sepharose Õ beads (GE Healthcare) per ml for 1 h at room temperature. Samples were centrifuged at 800g for 10 min, the supernatant removed and the beads transferred to a chromatography spin column (Bio-Rad), equilibrated with PBS. After washing the columns twice with 1 ml PBS, antibodies were eluted in two fractions, each with 400 ml elution buffer [0.1 M sodium citrate (pH 2.7), pH-neutralized with 40 ml 1 M Tris (pH 8.8)] per tube and dialysed overnight with PBS. IgG concentrations were determined with ELISA according to the manufacturer's instructions (Mabtech).
Screening for NR1 reactivity
HEK293T cells were transiently transfected with NR1 DNA (1 mg) as described (Prü ss et al., 2015) . Two days later, HEK cells on cover slips were fixed with methanol at À20 C for 4 min, washed in PBS, preincubated with 5% normal goat serum containing 2% bovine serum albumin and 0.1% Triton TM X-100, and incubated with the monoclonal human antibodies starting at a 1:10 dilution overnight at 4 C. Sections were washed in PBS and coverslips mounted with Immu-Mount TM (ThermoScientific). Double-labelling of transfected cells was performed using commercial monoclonal mouse anti-NR1 antibodies (1:100, Synaptic Systems; generated against amino acids 660-811 of rat GluN1).
Immunohistochemistry
Rat and mouse brain sections were used as unfixed tissue or after paraformaldehyde fixation, cut on a cryostat in 15 mm sections and mounted on glass slides. Fixed tissue was permeabilized in 0.1% Triton TM X-100 in PBS for 20 min and blocked in 10% normal goat serum for 30 min, unfixed tissue was not permeabilized. Monoclonal human antibodies were diluted to 30 mg/ml and sections incubated overnight at 4 C, human CSF was used undiluted. Further stainings included rabbit polyclonal anti-NR1 (1:100, Synaptic Systems; generated against amino acids 35-53 of rat GluN1), anti-MAP2 (1:500, Millipore).
Site-directed mutagenesis
Point mutation N368Q was introduced into the NR1 construct using the Stratagene QuikChange TM Mutagenesis kit according to manufacturer's instructions, and the mutant transiently transfected in HEK cells as described previously (Doss et al., 2014) .
Flow cytometry and epitope competition assay
Unfixed NR1-expressing HEK cells were incubated with monoclonal human antibodies (100 mg/ml) for 45 min, washed in PBS and incubated with an allophycocyanin-conjugated secondary anti-human antibody for 30 min. Median fluorescence intensity was measured using a FACSCanto TM II (BD Biosciences). For epitope competition, HEK cells were first incubated with commercial rabbit NR1 antibodies in increasing concentrations, washed, and incubated with human NR1 antibodies as above.
Primary hippocampal neurons
Brains from murine pups (postnatal Days 1-3) were transferred into Hanks balanced salt solution (HBSS) with 10 mM HEPES buffer (pH 7.3). For glial preparation, cortices were incubated at 37 C for 20 min with 0.5% trypsin/EDTA (TE) solution and transferred into astrocyte media (DMEM containing 0.45% glucose, 1000 U/ml penicillin, 1000 mg/ml streptomycin and 10% foetal bovine serum). Cortices were dissociated and grown in astrocyte media for 14 days. Astrocytes were trypsinated, washed and seeded with a density of 45 000 cells/well into 24-well plates to provide a glial feeding layer for neurons. Mitogenesis was stopped after 6 days by incubation for 24 h with 40.5 mM 5-fluoro-2-desoxyuridine and 102 mM uridine in DMEM. To condition the media for neuronal growth, astrocyte media was exchanged to neuron media (Neurobasal Õ Media A for postnatal neurons supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin and 0.5 mM L-alanyl-L-glutamine) the day before preparation. For neuronal preparation, hippocampi were incubated with 2.5% trypsin at 37 C for 15 min, washed three times in HBSS and taken up in 500 ml neuron media. Hippocampi were dissociated with a fire-polished, narrowed glass pipette, cells counted and plated at 20-40 000 cells/well in neuron media on 12 mm poly-L-lysine (PLL)-treated coverslips. After 4-5 h, attached neurons were transferred upsid-down on the glial feeding layer and cultured for 7-21 days. Distance between the layers was kept by small dots of paraffin that were placed on the coverslips prior to PLL treatment.
NMDAR cluster downregulation
Hippocampal neurons were incubated with 0.5 mg/ml human monoclonal NR1 or control antibody at 37 C for 18 h. Cells were fixed with methanol and stained with rabbit polyclonal anti-NR1 (1:100, Synaptic Systems) as above. The control antibody (mGo53) is a non-reactive human antibody previously described (Wardemann et al., 2003) . For each condition, 94 neurons were selected from three independent experiments, and three dendrite sections of 50 mm lengths were counted per cell.
In vivo binding of monoclonal antibodies
Eight-week-old C57Bl/6 mice were intravenously injected with a single dose of 60 mg monoclonal NR1 or control antibody. After 24 h, mice were euthanized, brains removed, unfixed parasagittal sections cut on a cryostat and stained with an anti-human immunoglobulin secondary antibody.
Electrophysiological recordings
Cultured murine hippocampal neurons [days in vitro (DIV) 13-15] were incubated with recombinant antibodies for 18 h at 0.5 mg/ml. Cells were transferred to a submerged recording chamber continuously perfused with extracellular buffer containing 140 mM NaCl, 2.4 mM KCl, 10 mM HEPES, 10 mM glucose, 2 mM CaCl 2 , and 1 mM MgCl 2 , pH adjusted to 7.3 with NaOH, 300 mOsm at room temperature. MNI-caged-Lglutamate (Tocris) was added at a final concentration of 100 mM for glutamate uncaging experiments, which were performed in the presence of the NMDAR co-agonist glycine (10 mM, Sigma), the GABA B R antagonist SCH 50 911 (10 mM, Tocris), the GABA A R antagonist Gabazine (2 mM, Tocris), and the AMPAR antagonist NBQX (10 mM, Tocris) in order to isolate NMDAR-mediated currents. Whole-cell voltage clamp recordings were performed with borosilicate glass electrodes (2-5 M) filled with 130 mM KMSO 3 , 4 mM KCl, 10 mM HEPES, 4 mM Mg-ATP, 0.2 mM EGTA, 4 mM NaCl, 0.3 mM NaGTP, 10 mM phosphocreatine-Na 2 ; pH adjusted to 7.3 with KOH, 295 mOsm. Series resistance (Rs) was monitored continuously throughout experiments; cells were rejected if Rs was 425 M or varied more than 30% during recordings. No Rs compensation was used. Photolysis of 'caged' glutamate was performed at 0.1 Hz with a 20 ms light pulse of a 355 nm DPSS laser system (Rapp Optoelectronics) coupled into the fluorescence light path of an Olympus BX-51 WI microscope, equipped with a 60Â, 0.9 NA-objective, resulting in an effective light spot diameter of 15 mm in the focal plane, which was targeted directly on the soma of the neuron.
Calcium uptake
Hippocampal neurons were incubated with 15 mg/ml human monoclonal NR1 (clones 003-102 and 007-168 from Patients 2 and 4, respectively) or control antibody (mGo53) (Wardemann et al., 2003) at 37 C for 18 h. The membrane permeant calcium sensitive dye Fluo-4 (Life Technologies) was dissolved at 4 mM in DMSO) and cells loaded with a 1:5000 dilution for 30 min at 37 C. Coverslips were rinsed in prewarmed HEPES-buffered Tyrode's solution (HBTS, 118 mM NaCl, 4.8 mM KCl, 2 mM HEPES, 2 mM CaCl 2 , 2mM MgCl 2 , 33 mM Glucose), and transferred into wells containing 300 ml HBTS with 10 mM NBQX. Calcium influx across NMDAR was stimulated with injection of 200 ml NMDA solution to a final concentration of 10 mM with no wash-out period. Live cell imaging was performed using an inverted fluorescence microscope (Olympus IX73) equipped with a complementary metal-oxide semiconductor (CMOS) camera (Zyla, Andor Technology) and LED illumination system (CoolLED, pE-100). A series of images was acquired at 800-ms intervals for 43.2 s at an excitation wavelength of 470 nm shortly before the stimulation to measure fluorescence intensity at resting Ca 2 + levels and after the stimulation. The fluorescence intensity for each time point on the neuronal somata was measured using NIH ImageJ software and corrected for the baseline fluorescence measured before NMDA application.
Methods to prevent bias
Immunohistochemical quantification (NMDAR-containing clusters) and electrophysiological (NMDAR current amplitudes and calcium influx) recordings were performed blinded to the presence of either control or NR1 antibodies.
Statistics
Hippocampal culture experiments (cluster density, NMDAR currents and calcium influx) were analysed using two-tailed Mann Whitney U-test. Data are mean AE SEM. The accepted level of significance for all of the tests was P 5 0.05.
Results
Only a small fraction of CSF B cells produce NMDAR antibodies
Immunofluorescence on brain sections using CSF from patients with NMDAR encephalitis shows characteristic antibody binding to hippocampus neuropil (Fig. 1A) , but commonly also to further epitopes, such as astrocytic and neuronal elements, which do not overlap with NMDAR expression in six of eight patients in the present study (Fig.  1B-D) . To characterize the broadness of the antibody repertoire expressed by CSF cells in patients with NMDAR encephalitis we isolated CD27 + CD38 + antibody-secreting cells and CD20 + IgD À CD27 + memory B cells from CSF of eight consecutive patients using flow cytometric single cell sorting (Fig. 1E) . All patients were diagnosed with NMDAR encephalitis based on the typical clinical picture, presence of CSF inflammation, and detection of NR1 autoantibodies in the CSF (Supplementary Table 1 ). The single purified antibody-secreting cells and memory B cells were then subjected to amplification, sequencing and cloning of their full-length immunoglobulin heavy (IGH) and corresponding immunoglobulin kappa (IGK) or lambda (IGL) light chain genes ( Supplementary Tables 2 and 3 ). Sequence analysis confirmed that sorted cells were antigen-experienced B cells, and that the majority of antibody-secreting cells and memory B cells carried somatically mutated immunoglobulin genes and had undergone class-switching predominantly to immunoglobulin G (Fig. 1F) . Immunoglobulin gene repertoire analysis showed no striking bias in V and J gene family usage or other antibody features compared to peripheral antibody-secreting cells and memory B cells as previously published (Tiller et al., 2007) (Supplementary Fig. 1 ). Next we cloned the IGH and corresponding IGK/IGL variable genes into immunoglobulin G1 expression vectors to generate recombinant monoclonal antibodies. These were tested for reactivity against the NR1 subunit of the NMDAR expressed on HEK cells ( Fig. 2A-D) . Of 170 monoclonal antibodies from eight donors, we identified nine with reactivity to NR1 (three non-expanded, three expanded clones; Table 1 ), belonging to three patients. NR1-reactive clones were derived from two antibody-secreting cells in Patient 2 (acute encephalitis, 1 week from onset), four antibody-secreting cells and two memory B cells in Patient 4 (acute encephalitis, 6 weeks), and one memory B cell in Patient 5 (remission phase, 12 weeks) (Supplementary Table 3) .
NMDAR reactivity was confirmed on murine primary hippocampal neurons (Fig. 2E, F and H-K), live cells (Fig. 2G ) and rat and mouse brain sections ( Fig. 2L and  M) . High-resolution double-labelling images showed largely overlapping patterns with a commercially available rabbit NR1 antibody (Fig. 2H-J) . NMDAR clusters co-localized with the staining of VGLUT1, a marker for excitatory presynaptic terminals (Fig. 2K) . On brain sections, human NR1 antibodies displayed a strong characteristic hippocampal neuropil staining (Fig. 2L ) and typical staining of cerebellar granule cells (Fig. 2M) . Intravenous injection of monoclonal antibodies into mice resulted in strong enrichment of NR1 (but not control) antibodies in the brain with high accumulation in the hippocampal neuropil (Fig. 2N ) and cerebellar granule cells (Fig. 2P) .
Interestingly, 495% of CSF-derived antibody-secreting cells and memory B cells that resulted in non-NMDARbinding recombinant antibodies showed strong reactivity Table 1 with further specific epitopes on brain sections, thus clearly outnumbering the NR1-reactive antibodies. The epitopes included endothelium, glial cells, neuronal surfaces of hippocampal granule cells, Purkinje neurons, or neuropil staining in cerebellum and hippocampus (Fig. 3) .
Monoclonal NR1 antibodies can be unmutated and target a small epitope of the amino terminal receptor domain
Sequence analysis showed that the NMDAR antibodies were polyclonal immunoglobulins and often carried somatic hypermutations. However, we also identified germline NMDAR antibodies suggesting that the antibody-secreting cells had developed from unmutated naïve precursors ( Supplementary Fig. 2 ). Several expanded clones were observed among NMDAR and non-NR1-reactive antibodies. Clonal members were identical in their somatic hypermutations pattern suggesting that diversification of the common ancestor happened before the cells proliferated. Binding of patients' antibodies to a small epitope of the amino-terminal domain of the NR1 subunit has been reported previously. We therefore generated an NR1 subunit construct with amino acid 368 mutated (N368Q) and tested the NR1-specific clones for their reactivity in transfected HEK cells. Indeed, binding to the mutant was eliminated for all monoclonal NR1 antibodies from different patients, including the germline-configured clones ( Fig. 4C and F) , while two commercial antibodies targeting different NR1 epitopes were still detected ( Fig. 4B and E) . Competition assays further confirmed that the commercial antibodies detected different , 011-116) , which are known to also highly express NR1 (c.f. Fig. 2M ), or to the neuropil of the molecular layer in different intensities and patterns (K, 007-146; L, 003-104) . Scale bars: A = 500 mm; B = 200 mm; C-E = 100 mm; F = 20 mm; G-L = 50 mm. ch.pl. = choroid plexus; DG = dentate gyrus; GCL = granule cell layer; PL = Purkinje cell layer; ML = molecular layer.
epitopes as the human monoclonal NR1 antibodies ( Fig.  4G and H).
Monoclonal NR1 antibodies disrupt synaptic NMDAR currents and morphology
To determine if NMDAR binding influenced neuronal cell function, we incubated primary murine hippocampal neurons with the purified monoclonal human NR1 or control antibody. Indeed, antibody-binding resulted in profound downregulation of NMDAR-positive synaptic clusters ( Fig. 5A and B) . Average cluster density was 8.4 per 50 mm dendrite length in the control group and 4.7 in the NR1 antibody-treated group, which represented a 445% reduction of NMDAR clusters (Fig. 5C ) (P 5 0.0001, Mann-Whitney U-test). We next examined whether the morphological changes after NR1 antibody treatment also lead to functional impairment in hippocampal neurons using whole cell patch clamp recordings. NMDAR-mediated currents were isolated in the presence of AMPA/kainate-and GABA receptor blockers. Laserinduced uncaging of glutamate triggered NMDARmediated currents of 220 AE 61 pA in control antibody-treated and 119 AE 15 pA in NR1 antibody-treated neurons ($46% reduction, Fig. 5D and E) (P = 0.016, Mann-Whitney U-test). In line with the electrophysiological observations, calcium imaging experiments using monoclonal NR1 antibodies from two different patients, revealed a profoundly reduced NMDA-induced calcium influx, affecting the total amount of calcium influx (area under the curve) as well as calcium peak concentration ( Fig. 5F -H) (P 5 0.0001, Mann-Whitney U-test).
Discussion
The present study provides data on the CSF antibody repertoire in NMDAR encephalitis and shows that binding of human monoclonal NR1 antibodies to NMDARs is sufficient to cause morphological and electrophysiological changes in neurons resulting from NMDAR downregulation. Thus, it provides ultimate proof that CSF-derived NR1 antibodies from patients with NMDAR encephalitis can solely cause these changes and that it did not depend on the presence of additional anti-neuronal antibodies, complement activation, or further undetermined molecules. It also provides evidence that seropositivity for the here described NMDAR autoantibodies must be considered a risk factor for neuropsychiatric symptoms (similar to a drug or toxin level), and supports the concept that CSF antibody titres are intraindividual disease biomarkers correlating with clinical remission (Gresa-Arribas et al., 2014) .
However, the present study demonstrated that NR1 antibody-producing cells are relatively rare in the CSF, making Figure 4 Epitope analysis of monoclonal human NR1 antibodies. HEK cells were transfected with wild-type NR1 (A-C) or a construct with amino acid 368 mutated (N368Q) (D-F). As exemplarily shown for clone 007-168, all human monoclonal NR1 (hNR1) antibodies strongly recognized NR1 (C), but staining of the mutant was eliminated (F). In contrast, a commercial mouse (msNR1) and rabbit anti-NR1 (rbNR1) antibody recognizing different NR1 epitopes bound to both wild-type (B) and N368Q (E). Staining of NR1-expressing HEK cells (G) with the monoclonal NR1 antibody resulted in high fluorescence intensity (H, black line). The signal was not reduced after preincubation with rabbit NR1 antibodies, further confirming the binding to different epitopes (H). FSC = forward scatter; SSC = side scatter.
up only $6% of antibody-secreting cells/memory B cells. This was surprising as most patients show intrathecal synthesis of NMDAR antibodies (Gresa-Arribas et al., 2014) associated with the presence of large numbers of antibodysecreting cells that can exceed 10% of all CSF cells (Dale et al., 2013) , suggesting that a large proportion of antibodysecreting cells might be disease-specific producing NMDAR antibodies. Despite the low frequency, NR1 antibodies might reach high concentrations in the brain tissue as autopsy reports from the acute phase of the encephalitis demonstrated increased antibody-secreting cell numbers in the meninges and brain parenchyma (Martinez-Hernandez et al., 2011) . Surprisingly, the vast majority of antibody-secreting cells/ memory B cells produced antibodies that did not bind to NR1, but reacted against further brain-expressed epitopes including neuronal surface antigens in hippocampus and cerebellum. The finding suggests that these cells are Cultures treated with control antibody for 18 h showed unchanged morphology (A, boxed area is enlarged in the bottom panel), while cultures treated with human monoclonal NR1 antibody showed profound loss of clusters (B). Quantification showed reduction of cluster density by 445% (P 5 0.0001) (C). NMDAR currents were evoked by UV light-assisted glutamate uncaging on the soma of cultured hippocampal neurons (D). Glutamate uncaging-evoked currents were profoundly reduced in NR1 antibody-treated neurons (P = 0.016) (E). NMDAR function in hippocampal cultures was further evaluated by neuronal stimulation with 10 mM NMDA; representative video sequences demonstrate fluorescence intensity of the calcium-sensitive dye Fluo4 at 0, 4 and 30 s after stimulation when pretreated for 18 h with non-neuronal control antibody (F) or different human monoclonal NR1 antibodies (G). Quantification of calcium influx (arbitrary units) showed marked reduction in NR1 antibody-treated cultures (P 5 0.0001) (H). Data are mean AE SEM from 53 independent experiments, Mann-Whitney U-test. n = 3 Â 50 mm sections of 94 neurons (C), n = 14 for both groups (D and E), n = 26-48 neurons (H).
specifically enriched in the CNS in which their antigens are present. Clonal expansions were observed for both NR1-and non-NR1-reacting B cells. Extensive future work will have to elucidate the target protein specificity of non-NR1 antibodies, and will show whether these antibodies can also change morphology and electrophysiological properties of neuronal receptors, which seems possible given their neuropil and neuronal surface reactivity. Thus, they could potentially contribute to the highly variable clinical phenotype of NMDAR encephalitis, ranging from isolated psychosis to severe cognitive impairment, hypoventilation or brainstem dysfunction.
The here described molecular features of NR1 autoantibodies support the concept that ectopically expressed NMDAR protein (such as in ovarian teratomas) can trigger NMDAR encephalitis (Day et al., 2014) . Generally, highly autoreactive bone marrow-derived B cells are regulated at central and peripheral tolerance checkpoints (Wardemann et al., 2003) . The presence of NMDAR germline antibodies suggests that tolerance induction is incomplete or absent against the non-peripheral neuronal protein NMDAR. In the absence of access to the brain the presence of rare peripheral anti-NR1 B cells may not pose a risk. Expression of this otherwise non-accessible protein on the tumour may explain positive selection and expansion of high-affinity NR1-reactive B cells. Once these clonally expanded and affinity-matured cells get access to the brain, local antigen-mediated activation of anti-NMDAR naïve and preexisting memory B cells may induce and fuel the disease progression.
In addition to previously reported immunoglobulin G1 and immunoglobulin G3 isotypes (Hughes et al., 2010) , immunoglobulin G2 NR1 antibodies can be part of the CSF repertoire. The surprisingly low number of somatic hypermutations in heavy and light chains (including even germline encoded antibodies), the finding that clonally expanded CSF B cells carried identical somatic hypermutations patterns, and the high NR1 antibody titres in serum suggest that these cells originated from peripheral immune responses rather than from clonal expansion and diversification in the CSF. NR1 antibodies were also cloned from persistent memory B cells suggesting that memory can be formed during encephalitis. Reactivation and differentiation into NR1-specific antibody-secreting cells may be associated with clinical relapses.
The recombinant human monoclonal antibodies will be useful tools for high resolution synaptic imaging and future research into the molecular mechanisms and clinical correlations in NMDAR encephalitis. Using the same methodology, monoclonal antibodies from patients with neuropsychiatric lupus (DeGiorgio et al., 2001) , monosymptomatic psychiatric NMDAR encephalitis (Deakin et al., 2014) , or NMDAR-immunoglobulin A antibodyassociated cognitive decline Doss et al., 2014) will be equally examined for pathogenicity, thus uncovering disease mechanisms of diverse neuropsychiatric phenotypes related to NMDAR autoimmunity.
